Boston Trust Walden Corp Sells 16,044 Shares of Chemed Corporation $CHE

Boston Trust Walden Corp reduced its position in Chemed Corporation (NYSE:CHE) by 7.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 205,197 shares of the company’s stock after selling 16,044 shares during the period. Boston Trust Walden Corp’s holdings in Chemed were worth $77,511,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Keybank National Association OH lifted its stake in Chemed by 8.2% during the 1st quarter. Keybank National Association OH now owns 1,371 shares of the company’s stock valued at $518,000 after acquiring an additional 104 shares during the period. Mitchell & Pahl Private Wealth LLC grew its stake in shares of Chemed by 10.3% in the first quarter. Mitchell & Pahl Private Wealth LLC now owns 1,590 shares of the company’s stock worth $601,000 after acquiring an additional 148 shares during the period. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Chemed by 20.3% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 62,264 shares of the company’s stock worth $23,520,000 after acquiring an additional 10,498 shares during the period. Pictet Asset Management Holding SA raised its holdings in shares of Chemed by 5.0% during the first quarter. Pictet Asset Management Holding SA now owns 2,305 shares of the company’s stock valued at $871,000 after purchasing an additional 110 shares during the last quarter. Finally, MBE Wealth Management LLC raised its holdings in shares of Chemed by 11.2% during the first quarter. MBE Wealth Management LLC now owns 687 shares of the company’s stock valued at $259,000 after purchasing an additional 69 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Price Performance

Shares of NYSE:CHE opened at $489.54 on Friday. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $6.50 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.52. The firm’s 50 day moving average price is $433.81 and its 200-day moving average price is $426.39. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $492.30.

Chemed (NYSE:CHE) last announced its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The company had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. During the same period in the previous year, the business posted $5.63 earnings per share. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Equities research analysts expect that Chemed Corporation will post 22.3 EPS for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s payout ratio is presently 13.08%.

Insiders Place Their Bets

In other news, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the sale, the director directly owned 4,578 shares in the company, valued at $2,047,876.74. This represents a 22.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. This represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada raised their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a report on Monday, April 27th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen cut Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, Weiss Ratings upgraded Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $501.50.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.